Latest News and Press Releases

Late-breaker presentation to include new clinical data from Cohort 1 in the Imagine-1 clinical trial for GM1 gangliosidosis, Friday, February 11Podium presentations on clinical trial designs for...

Present longer follow-up and clinical milestones for Cohort 1 of the Imagine-1 GM1 gangliosidosis clinical trial at the 18th Annual WORLDSymposium, February 11, 2022Dose first patients in Cohorts 2...

PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...

– Independent Data Monitoring Committee recommends proceeding with two additional planned patient cohorts, which are now being recruited in parallel – Positive safety profile, including no serious...

Exercised two additional options with University of Pennsylvania’s Gene Therapy Program aligned with company’s focus on CNS diseases with high unmet need Huntington’s disease, a fatal rare adult...

PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...

On track to report initial safety and 30-day biomarker data for cohort 1 from Imagine-1 global Phase 1/2 trial for PBGM01 for the treatment of infantile GM1 in 4Q21Activated multiple clinical sites...

PHILADELPHIA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...

PHILADELPHIA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for central nervous system (CNS)...